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Background: In the diagnosis of Alzheimer’s disease (AD), examining memory is predominant. Our aim was to analyse the potential
role of various cognitive domains in the cognitive evaluation of AD.
Methods: 110 individuals with clinically defined AD and 45 healthy control participants underwent neuropsychological evaluation
including Addenbrooke’s Cognitive Examination (ACE). AD patients were selected in three groups based on disease duration in
years (y) (Group 1: ≤2y n=36; Group 2: 2‐4y n=44, Group 3: ≥4y n=30). Covariance weighted intergroup comparison was performed
on global cognitive score and subscores of cognitive domains. Spearman’s rho was applied to study the correlation between
cognitive subscores and disease duration. Wilcoxon signed ranked test was used for within group analysis among ACE cognitive
subscores.
Results: Significant difference was found between ACE total scores among groups (χ2=119,1; p<0,001) with a high negative
correlation (p<0,001; r: -0,643). With longer disease duration, all the subscores of ACE significantly decreased (p’s <0,001).
Visuospatial score showed the strongest negative correlation with disease duration with a linear trajectory in decline (r: -0,85).
In the early phase of cognitive decline, verbal fluency was the most impaired cognitive subdomain (normalized value: 0.64), and it
was significantly reduced compared to all other subdomains (p’s<0.05).
Conclusion: We found that impairment of verbal fluency is the most characteristic feature of early cognitive decline, therefore it
might have crucial importance in the early detection of Alzheimer’s disease. Based on our results visuospatial assessment might be
an ideal marker to monitor the progression of cognitive decline in AD.
Key words: (3-5): Alzheimer’s disease, neuropsychology, cognitive domains, progression, diagnosis
Introduction
  
 Contribution to the field
While the role of memory impairment is a frequently observed aim of research studies, lower number of studies have
investigated the importance of visuospatial abilities and verbal fluency in the early recognition of Alzheimer’s disease and in the
monitoring of progression of cognitive decline. In the current study, we analyzed the cognitive profile of 110 rigorously selected
Alzheimer patients with various disease duration and 45 healthy controls. We analyzed the contribution of six cognitive domains
in the cognitive deficit of Alzheimer patients, namely orientation, memory, language, attention, verbal fluency and visuospatial
abilities. We demonstrated that verbal fluency is the most impaired cognitive subdomain in the initial phases of AD. We also
highlighted that only visuospatial scores follow a linear decline among the disease course indicating the priority of this cognitive
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Background: In the diagnosis of Alzheimer’s disease (AD), examining memory is 42 
predominant. Our aim was to analyse the potential role of various cognitive domains in the 43 
cognitive evaluation of AD.  44 
Methods: 110 individuals with clinically defined AD and 45 healthy control participants 45 
underwent neuropsychological evaluation including Addenbrooke’s Cognitive Examination 46 
(ACE). AD patients were selected in three groups based on disease duration in years (y) (Group 47 
1: ≤2y n=36; Group 2: 2-4y n=44, Group 3: ≥4y n=30). Covariance weighted intergroup 48 
comparison was performed on global cognitive score and subscores of cognitive domains. 49 
Spearman’s rho was applied to study the correlation between cognitive subscores and disease 50 
duration. Wilcoxon signed ranked test was used for within group analysis among ACE cognitive 51 
subscores.  52 
Results: Significant difference was found between ACE total scores among groups (χ2=119,1; 53 
p<0,001) with a high negative correlation (p<0,001; r: -0,643). With longer disease duration, 54 
all the subscores of ACE significantly decreased (p’s <0,001). Visuospatial score showed the 55 
strongest negative correlation with disease duration with a linear trajectory in decline (r: -0,85). 56 
In the early phase of cognitive decline, verbal fluency was the most impaired cognitive 57 
subdomain (normalized value: 0.64), and it was significantly reduced compared to all other 58 
subdomains (p’s<0.05).  59 
Conclusion: We found that impairment of verbal fluency is the most characteristic feature of 60 
early cognitive decline, therefore it might have crucial importance in the early detection of 61 
Alzheimer’s disease. Based on our results visuospatial assessment might be an ideal marker to 62 
monitor the progression of cognitive decline in AD. 63 
Key words: (3-5): Alzheimer’s disease, neuropsychology, cognitive domains, progression, 64 
diagnosis 65 
Introduction 66 
Currently there are around fifty million patients worldwide living with major 67 
neurocognitive disorders. This number is expected to triple by 2050, placing tremendous socio-68 
economic and medical burden on the society. Alzheimer’s disease (AD) is the leading cause of 69 
cognitive decline in older adults, accounting for two thirds of dementia cases worldwide (1). 70 
AD is characterised by gradual decline of cognitive function, affecting the social and 71 
communication skills as well. The histopathological hallmarks of the disease are the presence 72 
of extracellular amyloid plaques and intracellular neurofibrillary tangles (2). The initially 73 
affected neural structures are the hippocampus and the entorhinal cortex (3). These areas have 74 
crucial role in episodic memory, spatial orientation, and visuospatial abilities.  75 
The progression of the disease follows a pattern starting with mild cognitive impairment 76 
(MCI) as the prodromal phase of AD which may appear years prior to the dementia diagnosis 77 
of a patient. In most patients, MCI is characterised by memory complaints (amnestic type MCI) 78 
(4). According to the current DSM-V diagnostic guideline, short-term memory impairment 79 
becomes significant and learning difficulties appear in mild AD (5). In moderate AD, other 80 
cognitive domains are involved as well including language difficulties and impaired orientation. 81 
In severe AD, all cognitive domains are severely affected, communication skills and self-82 
reliance are lost (6). 83 
Current diagnostic guidelines advise the evaluation of a patient’s medical history, clinical 84 
examination to test mental status as core tests and cerebrospinal fluid analysis, neuroimaging 85 
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using magnetic resonance imaging or positron emission tomography as supportive diagnostic 86 
markers (7). Use of neuropsychological test batteries is recommended too (e.g. Montreal 87 
Cognitive Assessment- MoCA, Addenbrooke Cognitive Examination- ACE, Alzheimer's 88 
Disease Assessment Scale-Cognitive Subscale- ADAS-Cog). These tests focus mostly on 89 
assessing memory function and learning skills (the ratio of memory points/ maximum score is 90 
5/30 in MoCA, 35/100 in ACE and 35/70 in ADAS-Cog), while investigation of visuospatial 91 
abilities (the ratio of visuospatial points/ maximum score is 4/30 in MoCA, 5/100 in ACE and 92 
0/70 in ADAS-Cog), and verbal fluency (the ratio of verbal fluency points/ maximum score is 93 
1/30 in MoCA, 14/100 in ACE and 5/70 in ADAS-Cog), is relatively less detailed (8). However, 94 
they might hold significant diagnostic and prognostic potential as well (9) since they require 95 
organized activation of large neural networks (10-12). 96 
We hypothesised that in AD the severity of visuospatial- and verbal fluency performance 97 
decline is related to disease duration, as during the course of the neurodegenerative process 98 
more and more cortical areas involved in these functions become affected. Thus, our aim was 99 
to analyse the profile of cognitive impairment in AD patients with various disease duration 100 
exploring multiple cognitive domains (memory, orientation, attention, verbal fluency, language 101 
and visuospatial abilities) to assess their potential role in the early identification of AD and in 102 
the follow-up of the progression of cognitive decline. 103 
Methods 104 
Participants 105 
One hundred and ten participants (61 male, 49 female, mean age 73,1±6,6) with 106 
clinically defined AD and fourty-five healthy control participants (16 male, 29 female, mean 107 
age 68,6 ±7,40) were recruited from the Department of Neurology at the National Institute of 108 
Mental Health, Neurology and Neurosurgery (previously named National Institute of Clinical 109 
Neurosciences) in Budapest, Hungary. Informed written consent was obtained from each 110 
participant. The participants’ diagnosis was given based on the guidelines of the National 111 
Institute on Aging and the Alzheimer's Association (NIA-AA). (13) We sorted the participants 112 
with AD in three groups based on disease duration. Group 1 (n=36) included participants with 113 
disease duration up to two years, group 2 (n=44) with disease duration of 2 to 4 years, and group 114 
3 (n=30) with disease duration of 4 years or more. The healthy control individuals (Group 0; 115 
n=45) had negative neurological status and intact cognitive performance based on 116 
neuropsychology. Disease duration was calculated from the date of clinical diagnosis of AD. 117 
Heteroanamnestic data were also collected from family members and caregivers. Patients with 118 
a history of cognitive symptoms more than 2 years prior to the diagnosis of AD were not 119 
included in the current analysis. All methods were carried out in accordance with relevant 120 
guidelines and regulations. All experimental protocols were approved by The Hungarian 121 
Medical Research Council (reference number of ethical approval: 024505/2015). 122 
Clinical testing 123 
The participants underwent detailed medical, neurological, physical examination, as 124 
well as routine blood checks including thyroid functions and vitamin B12 levels. All patients 125 
had structural brain magnetic resonance imaging (MRI). MRIs were analyzed with visual 126 
inspection and medial temporal lobe atrophy (MTA) score was calculated. MTA=1 shows that 127 
choroid fissure is slightly widened among the hippocampi, MTA=2 shows mild enlargement of 128 
temporal horn and mild loss of hippocampal height, MTA=3 indicates moderate enlargement 129 
of temporal horn and moderate loss of hippocampal height, while MTA=4 shows the marked 130 
enlargement of temporal horn and the loss of internal hippocampal structure. (14) We 131 
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determined all the known risk factors of cognitive decline as exclusion criteria. Such risk factors 132 
included: untreated vitamin B12 deficiency or hypothyroidism, liver disease, renal 133 
insufficiency, alcohol or substance abuse, psychoactive drugs influencing cognitive function 134 
except for anti-dementia medications, clinically significant brain lesions (white matter lesions, 135 
stroke,) demyelinating conditions, head injury with loss of consciousness, hydrocephalus, 136 
schizophrenia, major depression, electroconvulsive therapy, HIV infection, syphilis or prior 137 
central nervous system infections.  138 
Neuropsychology 139 
All participants took part in neuropsychological evaluation. The assessments were 140 
conducted by trained neurologists or neuropsychologists. The language of evaluation was 141 
Hungarian. We selected the Hungarian version of Addenbrooke’s Cognitive Examination 142 
(ACE) (15) to assess cognitive function. It is known for its high specificity and sensitivity in 143 
the diagnosis of cognitive disorders (16). It tests six cognitive domains: orientation, attention, 144 
memory, verbal fluency, language and visuospatial abilities with a maximum score of 10; 8; 145 
35; 14; 28; 5 respectively, resulting in a maximum total score of 100. A total score of 83 set as 146 
cut off score has a 82% sensitivity at age>65 (17). Calculating the ratio of verbal fluency (V) 147 
and language (L) subscores/orientation (O) and delayed recall memory (M) subscores (VLOM 148 
ratio: (V+L)/(O+M)) enables differentiation between AD and frontotemporal dementia (FTD). 149 
The normal range of VLOM ratio is between 2.2 and 3.2. A value higher than 3.2 indicates 150 
Alzheimer-type dementia, while a value lower than 2.2 demonstrates frontotemporal type 151 
dementia. Visuospatial abilities are tested by asking the participant to copy two overlapping 152 
pentagons, to copy a cube and to draw a clock face with the hands set at a specified time. Verbal 153 
fluency is analyzed with two tasks to examine categorical fluency (naming of animals) and 154 
phonemic fluency (listing words starting with the letter “m”). Furthermore, the Mini-Mental 155 
State Examination (MMSE) is incorporated in the ACE enabling dementia severity assessment. 156 
Its total score ranges from 0 to 30, with higher scores indicating better cognitive performance. 157 
AD patients had MMSE<25, while controls had>25.  158 
Depression and anxiety may impair cognitive function (18, 19). To reduce the influence 159 
of depression and axiety on the data, we included the Beck Depression Inventory II (BDI-II) 160 
and Spielberger State and Trait Anxiety Inventory (STAI) in our test battery. A BDI-II score of 161 
less than 13 demonstrates minimal depression. Scores between 14 and 19 indicate mild 162 
depression, those between 20 and 28 refer to moderate depression, while a score of 29 or higher 163 
demonstrates severe depression. A low level of anxiety is indicated by a score of 45 or less for 164 
both state and trait anxiety. Participants with a BDI-II score of >13 or a STAI score of >45 were 165 
excluded from our analysis.  166 
 167 
Data analysis 168 
A recent study of de Boer et al. (20) reported significant differences in MMSE total 169 
score and cognitive subdomains’ scores between three study groups of 125 AD patients in total 170 
with various disease durations. Based on their results and our power calculations the probability 171 
was equal or greater than 80% to find a significant (alpha=0.05) difference between study 172 
groups in ACE total and cognitive subscores with a sample size of 150. Data distribution was 173 
tested using Shapiro-Wilk test. To test for significant differences (for intergroup comparisons) 174 
in demographic variables (e.g. age, years of education) one-way ANOVA and Kruskal-Wallis 175 
tests were used as parametric and non-parametric tests respectively based on the distribution of 176 
data. Statistical significance level was set at p<0.01 based on Bonferroni-correction due to 177 
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multiple comparisons. Due to the non-parametric distribution of data Spearman’s rho was used 178 
to study the correlation between disease duration (years) and cognitive function represented by 179 
the ACE total score. Between-group differences for ACE subscores were tested with covariance 180 
weighted (age, sex, disease onset) ANOVA and Kruskal-Wallis tests. Tukey test was applied 181 
for post-hoc analysis. Spearman correlation was applied for the connection of ACE subscores 182 
and disease duration. For within group analysis including normalized ACE subscores, 183 
normalization was applied with the achieved score in each cognitive domain divided with a 184 
maximum possible score of the same cognitive domain (e.g., 7/28 in language cognitive domain 185 
resulted in 0.25). Normalized data were compared with Wilcoxon-signed rank test because of 186 
the non-parametric distribution. IBM SPSS 20 software was used for statistical analysis. 187 
Results 188 
Demographic data 189 
Altogether 155 individuals (77 male: 49,7%, 78 females: 50,3%) participated in the 190 
study. The participants’ mean age was 71,8±7,1 years. The median duration of their education 191 
was 12 (12,0-17,0) years. Of the 155 participants 45 were cognitively intact control individuals 192 
while 110 were diagnosed with clinically defined Alzheimer’s disease. On brain MRI patients 193 
showed the characteristic cortical atrophy (bifrontal-bitemporal atrophy with reduced 194 
hippocampi). All patients had MTA score ≥ 3. 195 
Group 1 (n=36; disease duration of no more than 2 years) included 23 male (63,89%) 196 
and 13 female (36,11%) participants with a mean age of 70,7±7,4 years. In group 2 (n=44; 197 
disease duration of 2 to 4 years) there were 25 male (56,8%) and 19 female (43,2%) participants. 198 
Their mean age was 74,1±6,2 years. In group 3 (n=30; disease duration longer than 4 years) 13 199 
male (43,3%) and 17 female (56,7%) participants were selected, with a mean age of 74,6±5,4 200 
years. Group 0 included 45 control individuals (16 male (35,6%) and 29 female (64,4%)). Their 201 
mean age was 68,6±7,4 years. We studied between-group differences in sex, age, age at disease 202 
onset, education level, disease duration, ACE total score, ACE subscores and VLOM ratio 203 
(Table 1). Significant differences (p<0.001) were reported in almost all parameters except sex 204 
and age at disease onset.  205 
Insert Table 1.  206 
Relationship between ACE total score and disease duration 207 
Spearman’s rho showed a significant negative correlation between ACE total scores and 208 
disease duration (p<0,001; r:-0,643). To support this finding a one-way Kruskal-Wallis test was 209 
used confirming significant group effect on total ACE score (χ2=115,81; p<0,001). 210 
Between-group differences between ACE subscores 211 
One-way ANOVA was used to test between-group differences between the memory 212 
subscores. (Table 1). Significant between-group differences were found for memory (F=69,11; 213 
p<0,001). Kruskal-Wallis test was applied to study between-group differences between 214 
subscores of orientation, attention, verbal fluency, language, and visuospatial abilities (Table 215 
1). Significant between-group differences were found for orientation (χ2= 96,27; p<0,001), 216 
attention (χ2= 87,11; p<0,001), verbal fluency (χ2= 61,12; p<0,001), language (χ2=100,38; 217 
p<0,001) and visuospatial abilities (χ2=113,96; p<0,001). Age, sex and disease onset did not 218 
have significant modifier effect on between group differences (all p values>0.01). Tukey post-219 
hoc analysis revealed that Group 1 differs from Group 2, Group 3 and Group 0 in orientation 220 
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skills (all p values<0.001). Group 0 also differs from Group 2 and Group 3 in orientation skills 221 
(all p values <0,001) however, Group 2 and Group 3 are not significantly different (p=0,779). 222 
In terms of attention subscore, Group 1, Group 3 and Group 0 all differ from each other 223 
significantly (all p values <0,001). Group 2 differs from Group 3 and Group 0 significantly (all 224 
p values <0,001). However, Group 1 and Group 2 do not differ significantly (p=0,984). As for 225 
memory subscore, Group 2, Group 3 and Group 0 all differ from each other significantly (all p 226 
values <0,001). Group 1 differs from Group 3 and Group 0 significantly (all p values <0,001). 227 
However, Group 1 and Group 2 do not differ significantly (p=0,254). Regarding the subscore 228 
of verbal fluency, Group 0 differs from Group 1, Group 2 and Group 3 (all p values <0,001). 229 
However, Group 1 does not differ significantly from Group 2 and Group 3 (p=0,629 and 230 
p=0,017 respectively). Moreover, Group 2 does not differ significantly from Group 3 (p=0,198). 231 
Concerning language subscore, Group 1, Group 3 and Group 0 all differ from each other 232 
significantly (all p values <0,001). Group 2 differs from Group 1 and Group 0 significantly (all 233 
p values <0,001). However, Group 2 and Group 3 do not differ significantly (p=0,142). In terms 234 
of visuospatial subscore, all four groups differed significantly (all p values ≤ 0,001). (Figure 1). 235 
In the comparison to normal controls (Group 0), verbal fluency showed the largest difference 236 
in the first phase of the disease (Group 1). 237 
Insert Figure 1. 238 
Relationship between ACE subscores and disease duration 239 
Spearman’s rho was applied to test the relationship between all six ACE subscores and 240 
disease duration. Figure 2 demonstrates scatter plots for subscores in relation to disease duration 241 
(Figure 2).  242 
Insert Figure 2. 243 
Within-group differences between ACE subscores 244 
We applied Wilcoxon signed-ranked test for within-group difference analysis between 245 
ACE subscores. Differences between the normalized subscores are shown in Figure 3 and Table 246 
2.  247 
In Group 0 normalized subscore of orientation was significantly higher than the 248 
normalized subscore of memory (Z: -4,083; p<0,001), verbal fluency (Z:-3,95; p<0,001) and 249 
visuospatial abilities (Z: -2,10; p=0,036). However, the normalized subscore of orientation was 250 
significantly lower than the normalized subscore of language (Z: -2,32; p=0,021). There was 251 
no significant difference between the normalized subscores of orientation and attention. 252 
Normalized subscore of attention is significantly higher than the normalized subscore of 253 
memory (Z: -5,40; p<0,001), verbal fluency (Z: -4,60; p<0,001) and visuospatial abilities (Z: -254 
2,94; p=0,003). There was no significant difference between the normalized subscores of 255 
attention and language. Normalized subscore of memory was significantly lower than the 256 
normalized subscore of language (Z: -5,52; p<0,001) and visuospatial abilities (Z: -3,61; 257 
p<0,001). There was no significant difference between the normalized subscores of memory 258 
and verbal fluency. Normalized subscore of verbal fluency was significantly lower than the 259 
normalized score of language (Z: -4,68; p<0,001) and visuospatial abilities (Z: -3,75; p<0,001). 260 
Normalized subscore of language was significantly higher than the normalized subscore 261 
visuospatial abilities (Z: -2,82; p=0,005). 262 
In Group 1 normalized subscore of orientation was significantly higher than the 263 
normalized subscore of attention (Z: -2,34; p=0,019), memory (Z: -2,27; p=0,023) and verbal 264 
fluency (Z: -4,79; p<0,001). There was no significant difference between the normalized 265 
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subscores of orientation, language and visuospatial abilities.  Normalized subscore of attention 266 
was significantly higher that the normalized subscore of verbal fluency (Z: -4,14; p<0,001). 267 
However, normalized subscore of attention was significantly lower than the normalized 268 
subscore of language (Z: -5,23; p<0,001). There was no significant difference between the 269 
normalized subscores of attention, memory and visuospatial abilities.  Normalized subscore of 270 
memory was significantly higher than the normalizes subscore of verbal fluency (Z: -4,41; 271 
p<0,001). However, normalized subscore of memory was significantly lower than the 272 
normalized subscore of and language (Z: -5,23; p<0,001). There was no significant difference 273 
between the normalized subscores of memory and visuospatial abilities. Normalized subscore 274 
of verbal fluency was significantly lower than the normalized subscore of language (Z: -5,23; 275 
p<0,001) and visuospatial abilities (Z: -4,69; p<0,001). There was no significant difference 276 
between the normalized subscores of language and visuospatial abilities. 277 
In Group 2 normalized subscore of orientation was significantly higher than the 278 
normalized subscore of verbal fluency (Z: -3,62; p<0,001) and visuospatial abilities (Z: -4,38; 279 
p<0,001). However, normalized subscore of orientation was significantly lower than the 280 
normalized subscore of attention (Z: -3,23; p=0,001), memory (Z: -2,19; p=0,029). There was 281 
no significant difference between the normalized subscores of orientation and language. 282 
Normalized subscore of attention was significantly higher that the normalized subscore of 283 
verbal fluency (Z: -5,47; p<0,001), language (Z: -2,14; p=0,032) and visuospatial abilities (Z: 284 
-5,24; p<0,001). There was no significant difference between the normalized subscores of 285 
attention and memory. Normalized subscore of memory was significantly higher than the 286 
normalized subscore of verbal fluency (Z: -4,87; p<0,001), and visuospatial abilities (Z: -5,25; 287 
p<0,001). There was no significant difference between the normalized subscores of memory 288 
and language. Normalized subscore of verbal fluency was significantly higher than the 289 
normalized subscore of visuospatial abilities (Z: -3,31; p=0,001). However, normalized 290 
subscore of verbal fluency was significantly lower than the normalized subscore of language 291 
(Z: -3,55; p<0,001). Normalized subscore of language was significantly higher than the 292 
normalized subscore visuospatial abilities (Z: -4,07; p<0,001). 293 
In Group 3 normalized subscore of orientation was significantly higher than the 294 
normalized subscore of memory (Z: -3,86; p<0,001), verbal fluency (Z: -3,75; p<0,001) and 295 
visuospatial abilities (Z: -4,73; p<0,001). There was no significant difference between the 296 
normalized subscores of orientation, attention and language. Normalized subscore of attention 297 
was significantly higher than the normalized subscore of memory (Z: -3,10; p=0,002), verbal 298 
fluency (Z: -2,42; p=0,016) and visuospatial abilities (Z: -4,74; p<0,001). There was no 299 
significant difference between the normalized subscores of attention and language. Normalized 300 
subscore of memory was significantly higher than the normalized subscore of visuospatial 301 
abilities (Z: -4,46; p<0,001). However, normalized subscore of memory was significantly lower 302 
than the normalized subscore of language (Z: -4,32; p<0,001). There was no significant 303 
difference between the normalized subscores of memory and verbal fluency. Normalized 304 
subscore of verbal fluency was significantly higher than the normalized subscore of visuospatial 305 
abilities (Z: -4,47; p<0,001).  However, normalized subscore of verbal fluency was significantly 306 
lower than the normalized subscore of language (Z: -2,76; p=0,006). Normalized subscore of 307 
language was significantly higher than the normalized subscore visuospatial abilities (Z: -4,64; 308 
p<0,001). 309 
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Our study involved 110 clinically defined AD patients divided into three groups based on 312 
the length of disease duration. The control group (Group 0) consisted of 45 cognitively intact 313 
individuals. We found that verbal fluency is the most impaired cognitive domain in the first 2 314 
years of the disease course, and its disturbance is comparable to the memory impairment in the 315 
early phase of AD. Furthermore, since visuo-spatial abilities showed the most linear reduction 316 
among the groups with various disease lengths, it might serve as an ideal method for monitoring 317 
disease progression. 318 
Our analysis using correlation and between-group approaches showed that patients with 319 
longer disease duration have lower ACE global scores being in line with the current literature 320 
and confirming the fact that ACE indicates well the severity of AD (21) and global decline in 321 
cognition most frequently shows a linear pattern in AD (22, 23). 322 
While significant reduction in ACE subscores were present in a more advanced disease 323 
stage in case of memory, verbal fluency, language, orientation, attention, and visuospatial 324 
abilities; the pattern of the impairment of various cognitive domains demonstrated prominent 325 
differences. Other studies also showed that selective analysis of cognitive subdomains might 326 
reveal various trajectories of cognitive decline in AD (23). Episodic memory impairment is the 327 
hallmark of AD; however, controversial results exist. Some reports suggest that declined 328 
episodic memory functions associate with the early phase of AD (24, 25) while others suggest 329 
that prominent impairment occurs in the advanced phase of cognitive decline (6, 20). Our 330 
findings might reveal a deeper insight to the proposed problem. Our results show that memory 331 
is a highly affected cognitive domain already in the early course of the disease having 332 
significantly lower normalized score (0.78) than any other subscores except attention (0.77) and 333 
verbal fluency (0.64). However, during the first 2-3 years after the diagnosis the subsequent 334 
decrease of memory scores is not prominent (Group 1 and 2 do not differ significantly in these 335 
subscores) suggesting that sequential memory testing might not be the ideal tool to sensitively 336 
detect the progression of the cognitive decline. However, memory functions show rapid decline 337 
after 4 years of disease onset supporting earlier data that demonstrated that memory impairment 338 
is predominantly evident in the later stages of AD (20). This might suggest that while the global 339 
cognitive decline shows a continuously progressive course with the duration of the disease, 340 
episodic memory loss is becoming less pronounced while other domains contribute more in the 341 
linear global decline. From these data we might conclude that testing memory independently is 342 
not appropriate to monitor disease progression or estimate the effect of disease modifying 343 
interventions and drug trials in the mild and moderate phases of AD.  344 
We also found that verbal fluency was even more severely compromised at the early stage 345 
of AD than memory (0.78 normalized score for memory vs 0.64 normalized score for verbal 346 
fluency). Other reports also highlighted that verbal fluency is impaired even in amnestic type 347 
MCI (26), in the preclinical phase or mild phase of AD (27). Ideal verbal fluency tests could 348 
not be developed for routine screening of cognitive decline since there are controversial results: 349 
some studies propose that semantic (category) fluency might be an ideal tool for the early 350 
screening of dementia (28-30) while others demonstrated the superiority of phonemic (letter) 351 
fluency (26). However, a meta-analysis of 153 studies with 15990 participants proposed that 352 
semantic deficit is more prominent than phonemic (31). Based on our observations, it seems 353 
feasible that development of novel and more focused diagnostic procedures on verbal fluency 354 
might be an important direction for the early screening of cognitive decline.  355 
Our correlation analysis between disease duration and ACE subscores showed that 356 
patients with longer disease duration perform worse in all cognitive subdomain test. 357 
Visuospatial score showed remarkably strong negative correlation (larger than any other 358 
domains) with disease duration (r:-0.85) drawing special attention to this cognitive domain. 359 
Visuospatial skills are used to remember directions, addresses, and layout of familiar places. 360 
Visuospatial abilities are tested by asking the patient to copy two diagrams; to draw a clock 361 
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face with the hands set at a specified time; to count sets of dots; and to recognize four letters 362 
which are partially obscured. Although problems in visuospatial abilities are less well 363 
characterised symptoms of AD compared to memory impairment (9), visuospatial function 364 
monitoring could be ideal for assessing whether cognitive decline is progressive or not. 365 
Furthermore, it might be a useful cognitive test for outcome measures of drug trials or lifestyle 366 
interventional studies.  367 
There are limitations to our study. Firstly, positron emission tomography, cerebrospinal 368 
fluid analysis or genetic testing were not applied in the current experiment. Furthermore, 369 
cognitive decline might appear years preceding the diagnosis of AD, so disease duration might 370 
vary among the examined patients. We involved patients with short history of cognitive decline 371 
prior to the diagnosis of AD based on the reports of caregivers, however opinion of family 372 
members could be subjective. The strength of our study is the rigorous patient selection and the 373 
extensive application of different diagnostic methods. 374 
Conclusion 375 
AD is the leading cause of dementia in older adults. However, only sixteen percent of the 376 
older adults receive regular cognitive evaluation (32). Unfortunately, the estimated extent of 377 
missed or delayed diagnosis of AD is substantial (33). Evaluation of the impairment of verbal 378 
fluency seems to have crucial diagnostic potential in the early identification of AD.  379 
Visuospatial abilities have been found to be impaired in AD even in preclinical stages and are 380 
considered to hold diagnostic potential (9, 34). Furthermore, they might have a potential role in 381 
the assessment of progression of cognitive decline since they follow linear decline among the 382 
disease course, so testing visuospatial skill might be ideal in the validation phase of drug trials. 383 
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Tables 506 
Table 1. Demographic and clinical data of participants.  507 
Statistical tests applied were Chi-square for sex, ANOVA for parametric and Kruskal-Wallis 508 
for non-parametric statistics. One-way ANOVA analysis was used for between-group 509 
differences in memory. Kruskal-Wallis test was used for between-group differences in 510 
orientation, attention verbal fluency, language and visuospatial abilities. SD: standard 511 
deviation; MMSE: Mini-Mental State Examination IQ1-IQ3: interquartile range 512 
 513 
Parameter Total Group 0 Group 1 Group 2 Group 3 
p-
value 
Participants (n) 155 45 36  44  30  - 












Age (years) mean±SD 71,8±7,1  68,6±7,4 70,7±7,4 74,1±6,2  74,6±5,4  <0,001  
Age at disease onset 
(years) mean±SD 
70,2±6,4 
      - 
69,2±7,3 71,1±6,2  70,0±5,6  0,43 
Education (years) 






























ACE total score 














































































Memory mean± SD  21,0±4,9  25,1±1,8 21,9±3,1  20,5±4,4  14,2±3,0  <0,001 













































Table 2. Normalized ACE subscores for orientation, attention, memory, verbal fluency, 515 
language and visuospatial abilities per group. 516 
Normalization was performed by dividing the participant’s score in each cognitive domain by 517 
the highest score possible of the same domain. (eg. 5/10 in the orientation domain resulted in a 518 
normalized score of 0,5). Differences among the cognitive subscores were compared with 519 
Wilcoxon-signed ranked test. <, > indicate the statistically significant differences with the 520 
direction (p<0.05), while = signals unsignificant differences (p>0.05). SD: standard deviation, 521 
O: orientation, A: attention, M: memory, VF: verbal fluency, L: language, VS: visuospatial 522 






Group 0 Group 1 Group 2 Group 3 
Orientation Mean 0,98 0,84 0,68 0,65 
SD 0,05 0,13 0,15 0,13 













Attention Mean 0,99 0,77 0,76 0,61 
SD 0,03 0,15 0,19 0,17 











Memory Mean 0,90 0,78 0,73 0,51 
SD 0,06 0,11 0,16 0,11 












Mean 0,87 0,64 0,60 0,52 
SD 0,17 0,15 0,17 0,15 
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Language Mean 1,00 0,84 0,70 0,64 
SD 0,995 0,08 0,16 0,14 
Differences L>VS L=VS L>VS L>VS 
Visuospatial 
abilities 
Mean 0,96 0,81 0,50 0,25 
SD 0,08 0,15 0,23 0,19 
 525 
Legends 526 
Figure 1. Between group differences for cognitive subdomains. Orientation (A) was impaired 527 
in AD from the first two years of the disease compared to healthy controls (Group 1 vs Group 528 
0) and showed gradual decline (rapid decline in the first 4 years and remains constant 529 
afterward). Attention (B) was impaired initially (Group 0 vs Group 1), remained relatively 530 
preserved in the middle of the disease (Group 1 vs Group 2) and deteriorated again in the later 531 
phase (Group 2 vs Group 3). Memory (C) was also impaired from the first phase (Group 1 vs 532 
Group 0) but did not show prominent changes in the first 4 years of the disease (Group 1 vs 533 
Group 2), while rapid decline was detectable in the later phase (Group 2 vs Group 3). Verbal 534 
fluency (D) was highly damaged (largest difference between Group 0 and Group 1) in the first 535 
phase and did not decline further significantly. Language (E) was reduced initially (Group 1 vs 536 
Group 0) and linear decline was detectable in the first 4 years; however, changes were not so 537 
prominent at the end of the disease course (only Group 2 and Group 3 did not differ 538 
significantly). Visuospatial abilities (F) were reduced from the first phase also (Group 1 vs 539 
Group 0) and linear deterioration was highlighted (all groups differed significantly).  * indicates 540 
significant differences (p<0.01). 541 
Figure 2 Correlation analysis between ACE subscores and disease duration (in years) using 542 
Spearman’s rho. Significant negative correlation is present between all six subscores of 543 
orientation (A), attention (B), memory (C), verbal fluency (D), language (E) and visuospatial 544 
(F) scores (all p’s<0.05). Visuospatial abilities associate with the steepest r line.  545 
 546 
Figure 3. Within-group difference analysis for normalized ACE subscores. The contribution of 547 
verbal fluency in the cognitive maximum scores is the smallest in Group 1, suggesting 548 
prominent early impairment of this domain in the first phase of the disease. Noticeably, while 549 
the relative contribution of all cognitive domains did not change visually remarkably among 550 
the groups with various disease course, visuospatial abilities showed linear reduction in relative 551 
ratios.  552 
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